Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Short-term Investments (2017 - 2025)

Cue Biopharma's Short-term Investments history spans 7 years, with the latest figure at $7.0 million for Q3 2025.

  • For Q3 2025, Short-term Investments changed N/A year-over-year to $7.0 million; the TTM value through Sep 2025 reached $7.0 million, changed N/A, while the annual FY2023 figure was $287000.0, 98.84% down from the prior year.
  • Short-term Investments for Q3 2025 was $7.0 million at Cue Biopharma, up from $470000.0 in the prior quarter.
  • Across five years, Short-term Investments topped out at $29.5 million in Q3 2022 and bottomed at $287000.0 in Q4 2023.
  • The 3-year median for Short-term Investments is $6.0 million (2023), against an average of $9.7 million.
  • The largest YoY upside for Short-term Investments was 98.84% in 2023 against a maximum downside of 98.84% in 2023.
  • A 3-year view of Short-term Investments shows it stood at $24.7 million in 2022, then tumbled by 98.84% to $287000.0 in 2023, then skyrocketed by 2339.02% to $7.0 million in 2025.
  • Per Business Quant, the three most recent readings for CUE's Short-term Investments are $7.0 million (Q3 2025), $470000.0 (Q2 2025), and $912000.0 (Q1 2025).